Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ospemifene Efficacy and Safety in VVA
NCT00566982Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Oct 2007
- Primary completion
- Jul 2009
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in vulvovaginal atrophy (VVA) comparing Ospemifene 60 mg/day with Placebo (2 arms). Primary endpoints: Percentage of Parabasal Cells in Maturation Index of Vaginal Smear at 12 weeks, Percentage of Superficial Cells in Maturation Index of Vaginal Smear at 12 weeks and 1 more. Started Oct 2007; status: completed.
02
Drugs
ospemifene
03
Conditions
vulvovaginal atrophy (VVA)
Beyond the preview
Go deeper on NCT00566982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00566982.